Submitted by Anonymous (not verified) on 13 July 2026 - 15:52
Human medicines European public assessment report (EPAR): Libmyris, adalimumab, Date of authorisation: 12/11/2021, Revision: 10, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Libmyris, adalimumab, Date of authorisation: 12/11/2021, Revision: 10, Status: Authorised